Patents by Inventor Alain Vasserot

Alain Vasserot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10130628
    Abstract: This disclosure provides a technology for managing the sensation of pain in a subject in need thereof. Treatment methods according to this invention include administering to the subject a formulation that contains an effective amount of (4-[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone).
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: November 20, 2018
    Assignees: UNITY BIOTECHNOLOGY, INC., BUCK INSTITUTE FOR RESEARCH ON AGING, THE JOHNS HOPKINS UNIVERSITY, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Nathaniel David, Albert Davalos, Remi-Martin Laberge, Judith Campisi, Marco Demaria, Alain Vasserot, Chaekyu Kim, Okhee Jeon, Jennifer Elisseeff, James L. Kirkland, Tamar Tchkonia, Yi Zhu
  • Patent number: 9925170
    Abstract: Provided herein are pharmacologically active compositions suitable for topical application or injection directly for fat treatment without the need for surgical intervention.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: March 27, 2018
    Assignee: Kythera Biopharmaceuticals, Inc.
    Inventors: Serge Lichtsteiner, Alain Vasserot, Neil Poloso
  • Publication number: 20170326136
    Abstract: This disclosure provides a technology for managing the sensation of pain in a subject in need thereof. Treatment methods according to this invention include administering to the subject a formulation that contains an effective amount of (4-[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone).
    Type: Application
    Filed: April 6, 2017
    Publication date: November 16, 2017
    Inventors: Nathaniel David, Albert Davalos, Remi-Martin Laberge, Judith Campisi, Marco Demaria, Alain Vasserot, Chaekyu Kim, Okhee Jeon, Jennifer Elisseeff
  • Publication number: 20170095447
    Abstract: Provided herein are pharmacologically active compositions suitable for topical application or injection directly for fat treatment without the need for surgical intervention.
    Type: Application
    Filed: September 30, 2016
    Publication date: April 6, 2017
    Applicant: KYTHERA BIOPHARMACEUTICALS, INC.
    Inventors: Serge Lichtsteiner, Alain Vasserot, Neil Poloso
  • Patent number: 7378244
    Abstract: Telomerase reverse transcriptase is part of the telomerase complex responsible for maintaining telomere length and increasing the replicative capacity of progenitor cells. Telomerase activity is turned off in mature differentiated cells, but is turned back on again in hyperplastic diseases, including many cancers. This disclosure provides regulatory elements that promote transcription in cells that express telomerase reverse transcriptase (TERT). The disclosure also provides systems using TERT promoter sequences for identifying compounds that can be used to modulate telomerase expression.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: May 27, 2008
    Assignee: Geron Corporation
    Inventors: Gregg B. Morin, Serge Lichtsteiner, Alain Vasserot, Robert Adams, William H. Andrews
  • Publication number: 20060281106
    Abstract: Telomerase reverse transcriptase is part of the telomerase complex responsible for maintaining telomere length and increasing the replicative capacity of progenitor cells. Telomerase activity is turned off in mature differentiated cells, but is turned back on again in hyperplastic diseases, including many cancers. This disclosure provides regulatory elements that promote transcription in cells that express telomerase reverse transcriptase (TERT).
    Type: Application
    Filed: April 25, 2006
    Publication date: December 14, 2006
    Inventors: William Andrews, Gregg Morin, Serge Lichtsteiner, Alain Vasserot, Robert Adams, Lisa Cardoza, Jane Lebkowski
  • Publication number: 20060269549
    Abstract: The present invention relates to TNF-? binding molecules and nucleic acid sequences encoding TNF-? binding molecules. In particular, the present invention relates to TNF-? binding molecules with a high binding affinity, a high association rate, a low dissociation rate with regard to human TNF-? and that are capable of neutralizing TNF-? at low concentrations. Preferably, the TNF-? binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).
    Type: Application
    Filed: January 8, 2004
    Publication date: November 30, 2006
    Inventors: Jeffry Watkins, Alain Vasserot, David Marquis, William Huse
  • Publication number: 20060257407
    Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: April 28, 2006
    Publication date: November 16, 2006
    Inventors: Yan Chen, Debra Gardner, David Knight, Michael Lark, Bailin Liang, David Shealy, Xiao-Yu Song, Vedrana Stojanovic-Susulic, Raymond Sweet, Susan Tam, Sheng-Jiun Wu, Jing Yang, David Marquis, Eric Smith, Alain Vasserot
  • Publication number: 20060166254
    Abstract: This invention provides purified telomerase and methods of purifying it. The methods involve the use of several sequential steps, including the use of matrices that bind molecules bearing negative charges, matrices that bind molecules bearing positive charges, intermediate-selectivity matrices, methods that separate molecules based on their size, shape, or buoyant density, and by affinity purification.
    Type: Application
    Filed: March 13, 2006
    Publication date: July 27, 2006
    Inventors: Scott Weinrich, Edward Atkinson, Serge Lichtsteiner, Alain Vasserot, Ronald Pruzan
  • Publication number: 20060140932
    Abstract: The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low kooff values), reduced deamidation compared to the native antibody, and can be used to treat various diseases such as rheumatoid arthritis, osteoarthritis, or neuroinflammation.
    Type: Application
    Filed: January 21, 2004
    Publication date: June 29, 2006
    Inventors: Craig Dickinson, Alain Vasserot, Jeffry Watkins, Jirong Lu
  • Publication number: 20050089883
    Abstract: This invention provides purified telomerase and methods of purifying it. The methods involve the use of several sequential steps, including the use of matrices that bind molecules bearing negative charges, matrices that bind molecules bearing positive charges, intermediate-selectivity matrices, methods that separate molecules based on their size, shape, or buoyant density, and by affinity purification.
    Type: Application
    Filed: March 26, 2004
    Publication date: April 28, 2005
    Inventors: Scott Weinrich, Edward Atkinson, Serge Lichtsteiner, Alain Vasserot, Ronald Pruzan